This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y
by Zacks Equity Research
Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.
SNYNegative Net Change RHHBYNegative Net Change FOLDPositive Net Change TAKNegative Net Change
biotechs earnings pharmaceuticals
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
RGENNegative Net Change ADPTPositive Net Change AXSMPositive Net Change BNTXNegative Net Change
biotechs earnings
Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.
JNJNegative Net Change RHHBYNegative Net Change BMYNegative Net Change HALOPositive Net Change
biotechs
Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
LLYNegative Net Change AMGNPositive Net Change ABBVNegative Net Change BHVNNegative Net Change
biotechs earnings
Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.
ADPTPositive Net Change KODPositive Net Change ASLNNegative Net Change MISTNegative Net Change
biotechs earnings
7 Inverse ETFs Riding High on Nasdaq Sell-Off
by Sweta Killa
We have highlighted seven inverse ETFs that benefited the most from the Nasdaq sell-off.
AMZNPositive Net Change LRCXNegative Net Change QCOMNegative Net Change NFLXPositive Net Change ALGNPositive Net Change FBPositive Net Change GOOGLNegative Net Change QRVONegative Net Change TZAPositive Net Change LABDPositive Net Change SQQQNegative Net Change TECSNegative Net Change SOXSPositive Net Change SSGNegative Net Change FNGDNegative Net Change
biotechs etfs fang semiconductor tech-stocks
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.
ILMNNegative Net Change BSXPositive Net Change EYENegative Net Change
biotechs medical
Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season
by Zacks Equity Research
Anavex Life Sciences (AVXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AVXLNegative Net Change
biotechs medical
Indexes Sink into Close, Q1 Reports for NVAX, WYNN & More
by Mark Vickery
The Nasdaq was -2.55% Monday, its worst single trading day in almost two months.
WYNNNegative Net Change NVAXNegative Net Change RBLXPositive Net Change
biotechs earnings tech-stocks
Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.
ADMANegative Net Change BNGOPositive Net Change AVROPositive Net Change
biotechs
Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More
by Kinjel Shah
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.
PRTANegative Net Change CPRXPositive Net Change MYOVPositive Net Change HRMYNegative Net Change
biotechs
Why ADMA Biologics (ADMA) Might Surprise This Earnings Season
by Zacks Equity Research
ADMA Biologics (ADMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADMANegative Net Change
biotechs medical
Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.
RHHBYNegative Net Change PFENegative Net Change EXELPositive Net Change BMYNegative Net Change
biotechs pharmaceuticals
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.
NVONegative Net Change GILDNegative Net Change VKTXNegative Net Change ICPTPositive Net Change
biotechs earnings
Ocugen (OCGN) Miss Earnings & Revenues Estimates in Q1
by Zacks Equity Research
Ocugen (OCGN) miss earnings and revenues estimates in the first quarter of 2021. Stock down.
OCGNPositive Net Change
biotechs
Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View
by Zacks Equity Research
Moderna (MRNA) reports first profitable quarter on the back of its success with COVID-19 vaccine. The number of COVID-19 vaccine doses delivered in the first quarter add up to 102 million.
AZNNegative Net Change MRKNegative Net Change MRNANegative Net Change VRTXNegative Net Change
biotechs earnings
Stock Market News for May 7, 2021
by Zacks Equity Research
Wall Street closed sharply higher on Thursday following strong labor market Data.
PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals
Company News for May 7, 2021
by Zacks Equity Research
Companies In The News Are: IRM, BUD, W, REGN.
REGNNegative Net Change IRMNegative Net Change BUDNegative Net Change WPositive Net Change
biotechs consumer-staples reit retail
Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.
ABBVNegative Net Change RETAPositive Net Change AVIRPositive Net Change BNTXNegative Net Change
biotechs earnings
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
by Zacks Equity Research
Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.
RHHBYNegative Net Change RGENNegative Net Change PRTANegative Net Change PBYINegative Net Change
biotechs
Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BNTXNegative Net Change
biotechs medical
Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.
MRKNegative Net Change BMYNegative Net Change IOVAPositive Net Change AVIRPositive Net Change
biotechs earnings
Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.
RHHBYNegative Net Change BMYNegative Net Change EPZMPositive Net Change ASLNNegative Net Change
biotechs earnings
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
BIIBNegative Net Change ALXNPositive Net Change GILDNegative Net Change AMGNPositive Net Change IBBNegative Net Change XBINegative Net Change BBHNegative Net Change
biotechs etfs
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider Q1 loss on increased R&D expenses.
JNJNegative Net Change GILDNegative Net Change BMYNegative Net Change FATENegative Net Change
biotechs earnings